Contract development and manufacturing organisation (CDMO) — Recipharm and Kancera, a development company focused on cancer therapy, have entered into a contract for the development and manufacture of the pharmaceutical candidate KAND567.
Structured collaboration
The pharmaceutical candidate, KAND567, blocks the fractalkine system and has demonstrated an effective ability to counteract the onset of autoimmune disorders in preclinical disease models. Future clinical studies will involve oral administration of KAND567 in capsule form.
To be able to fill capsules with the cancer therapy and ensure it can be effectively released Recipharm, as part of the agreement, will develop the preparation and manufacture the pharmaceutical product. This work will be performed at the company’s facility in Solna.
“We are happy to be able to contribute to the development of a new drug with the potential to be of great medical value,” commented Torkel Gren, general manager at Recipharm in Solna. “We have extensive experience in developing drugs for clinical trials as well as commercial manufacture and this will be very valuable in the collaboration with Kancera.”
“The decision to commence development of capsules for an active dosage of KAND567 shows that Kancera has reached an important milestone in the Fractalkine project,” added Thomas Olin, CEO of Kancera. “We are delighted to now be collaborating with Recipharm to produce the pharmaceutical product that will be used to study how KAND567 can help patients.”